TMEM184C

Across TCGA pan-cancer cohorts, TMEM184C Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMEM184C data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TMEM184C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM184C expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

BLCA, KIRP, and KIRC are the cancer types where TMEM184C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.052	0.688	<.001	30	view →
KIRP	DFS	Median	All	0.038	0.920	<.001	22	view →
KIRC	OS	Median	All	0.057	0.881	<.001	12	view →
STAD	DFS	Median	III,IV	1.000	0.337	.039	6	view →
COAD	OS	Median	II,III,IV	0.168	0.788	.005	6	view →
UCEC	DFS	Median	All	1.000	0.630	.032	4	view →
LGG	OS	Median	All	0.294	0.799	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMEM184C–BLCA (OS)

Open the BLCA breakdown →